Valneva Shares Plunge 7%, Downgraded to 'Sell' by Goldman Sachs

Key Catalyst for the Session

The main catalyst for the session is the revision published on April 22 by Goldman Sachs, which downgraded its recommendation on Valneva from 'neutral' to 'sell', while also lowering its price target from €3.25 to €2.15. This new target is approximately 11% below the current price of €2.41, suggesting further downside potential according to the American bank. Goldman Sachs' decision weighs heavily on the stock, which is down 7.1% compared to the previous day's close (€2.59). Over the past week, Valneva has lost nearly 9%. The next financial event to watch will be the publication of the first-quarter results, scheduled for May 7, followed by the annual general meeting on June 1.

Technical Analysis of the Stock

From a technical standpoint, the stock's configuration remains particularly tense. The price of €2.41 is now below the lower Bollinger Band (€2.50), a signal usually associated with an oversold condition. The RSI at 31 confirms this reading by nearing the conventional threshold of 30, territory generally considered as oversold. Furthermore, the stock is trading well below its 50-day (€3.84) and 200-day (€3.89) moving averages, indicating a firmly established downward trend. The technical support identified at €2.55 has already been breached during the session, potentially paving the way for further tensions. On the broader markets, the CAC 40 is down 0.39% at 8,203 points in a generally cautious environment. Among comparable pharmaceutical sector stocks, Sanofi remains stable (+0.09%) while UCB is down 1.74%. Across the Atlantic, major names like Eli Lilly and Johnson & Johnson also showed declines at the day's close.